Edition:
United States

People: Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

4.12USD
28 Apr 2017
Change (% chg)

$-0.10 (-2.37%)
Prev Close
$4.22
Open
$4.23
Day's High
$4.23
Day's Low
$4.11
Volume
2,903,282
Avg. Vol
6,723,851
52-wk High
$7.15
52-wk Low
$2.62

Shailubhai, Kunwar 

Dr. Kunwar Shailubhai is a Chief Scientific Officer of the Company. He served as our Chief Scientific Officer since July 2008. From March 2004 until July 2008 he served as Senior Vice President, Drug Discovery, of Synergy which at that time was a subsidiary of Callisto Pharmaceuticals, Inc. (“Synergy DE”). From May 2003 until March 2004, Dr. Shailubhai served as Executive Vice President, Research and Development of Synergy DE. From 2001 to April 2003, Dr. Shailubhai held the position of Vice President, Drug Discovery at Synergy DE where he was chiefly responsible for the preclinical development of our GC-C agonist program for drugs to treat colon cancer and GI inflammation. Between 1993 and 2000, he was with Monsanto Company, serving as Group Leader of the cancer chemoprevention group. Dr. Shailubhai previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology in 1984 from the University of Baroda, India, and his M.B.A. in 2001 from the University of Missouri, St. Louis.

Basic Compensation

Total Annual Compensation, USD 424,800
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,159,740
Fiscal Year Total, USD 1,584,540

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gary Jacob

4,211,680

Gary Gemignani

--

Marino Garcia

--

Patrick Griffin

1,195,750

Troy Hamilton

1,362,920

Bernard Denoyer

707,434
As Of  30 Dec 2015